Search Results 631-640 of 12825 for hypercoagulable
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find ...
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based ...
New drug may reduce need for aortic valve surgeries by slowing disease progression. ROCHESTER, Minn. — Aortic valve stenosis (AVS) is a significant health ...
This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
Study finds little increased risk of injury in high-intensity functional training program. Jay Furst. December 5, 2019. MayoClinicRadio podcast: 11/30/19 ...
About this study. Post market prospective, non-randomized, single-arm, multicenter study, designed to demonstrate dose response of an ablation system using ...
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival ...
Learn about the symptoms, causes and treatment of this blood vessel disease, also called IgA vasculitis, that causes a purplish rash on the lower legs.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.